Business World: Biogen Idec, Elan, & Tysabri (Natalizumab) and MS
From the AP, via the New York Times website:
FDA Panel Supports MS Drug's Market Return
By THE ASSOCIATED PRESS
Published: March 8, 2006
Filed at 11:24 a.m. ET
WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should allow multiple-sclerosis drug Tysabri back on the market.
The drug's manufacturers, Biogen Idec Inc. and Elan Corp., pulled the drug in February 2005 after two patients developed a rare brain disorder, known as progressive multifocal leukoencephalopathy, or PML, and one died. A third patient was later discovered to have PML and also died.
The 12-member panel voted unanimously to support the drug's return.
The FDA usually follows its panel's advice, but isn't required to do so. The agency is expected to make a final decision by the end of the month.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
FDA Panel Supports MS Drug's Market Return
By THE ASSOCIATED PRESS
Published: March 8, 2006
Filed at 11:24 a.m. ET
WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should allow multiple-sclerosis drug Tysabri back on the market.
The drug's manufacturers, Biogen Idec Inc. and Elan Corp., pulled the drug in February 2005 after two patients developed a rare brain disorder, known as progressive multifocal leukoencephalopathy, or PML, and one died. A third patient was later discovered to have PML and also died.
The 12-member panel voted unanimously to support the drug's return.
The FDA usually follows its panel's advice, but isn't required to do so. The agency is expected to make a final decision by the end of the month.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
posted by Anthony Risser at 11:45 AM
0 Comments:
Post a Comment
<< Home